Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956939 · ClinicalTrials.gov registry record
Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 38
- Enrollment target
NCT04956939 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 38 participants.
The verdict
NCT04956939 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 38 participants
- Enrollment target
Study Summary
Levodopa (LD) is an effective treatment to control symptoms of Parkinson's disease (PD). However, the response to (the effectiveness) LD changes over time and patients require higher and more frequent LD doses for treatment. The purpose of this study is to identify what reasons or causes might influence the changes in LD effectiveness, particularly if intestinal bacteria contribute to the breakdown of LD in patients with PD. This study is an observational cohort proof-of-concept study that follows PD patients who take PD at high-frequency doses and low-frequency doses. . Each PD patient will have a household healthy control/spouse enrolled into the study. Single patients with no spouse will still be eligible to enroll.
Interventions
- DRUG Low dose levodopa
- DRUG High dose levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-07-17 |
| Est. Completion | 2021-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956939
The ClinicalTrials.gov registry entry for NCT04956939 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Low dose levodopa is the first listed.
NCT04956939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04956939 about?
NCT04956939 is a clinical study titled "Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease". Levodopa (LD) is an effective treatment to control symptoms of Parkinson's disease (PD). However, the response to (the effectiveness) LD changes over time and patients require higher and more frequent LD doses for treatment. The purpose of this study is to identify what reasons or causes might influ...
What is the current status of trial NCT04956939?
This trial is currently completed. The enrollment target is 38 participants. The study started on 2018-07-17. Estimated completion is 2021-03-31.
What interventions are being tested in trial NCT04956939?
The interventions under investigation include: Low dose levodopa (DRUG), High dose levodopa (DRUG).
Who is sponsoring clinical trial NCT04956939?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.